25 Jun 2026 Avacta Announces U.S. FDA Agreement on Pivotal Trial Design for AVA6000 in Patients with Salivary Gland Cancer Investors | Therapeutics
01 Jun 2026 Avacta presents updated clinical data showing encouraging early efficacy signals for AVA6000 in salivary gland cancers at ASCO 2026 Investors | Therapeutics